John K. Erban

5.9k total citations · 2 hit papers
62 papers, 3.9k citations indexed

About

John K. Erban is a scholar working on Oncology, Cancer Research and Hematology. According to data from OpenAlex, John K. Erban has authored 62 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 21 papers in Cancer Research and 12 papers in Hematology. Recurrent topics in John K. Erban's work include Breast Cancer Treatment Studies (19 papers), Cancer Treatment and Pharmacology (10 papers) and Cancer Risks and Factors (8 papers). John K. Erban is often cited by papers focused on Breast Cancer Treatment Studies (19 papers), Cancer Treatment and Pharmacology (10 papers) and Cancer Risks and Factors (8 papers). John K. Erban collaborates with scholars based in United States, United Kingdom and Czechia. John K. Erban's co-authors include Bruce Furie, Barbara C. Furie, Gary E. Gilbert, Roberta Bonfanti, Denisa D. Wagner, Eric Larsen, Alessandro Celi, John M. Leong, Jenifer Coburn and Peter M. Ravdin and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

John K. Erban

61 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PADGEM protein: A receptor that mediates the interaction of activated platelets with neutrophils and monocytes

1989 738 citations Eric Larsen, Alessandro Celi et al. Cell profile →
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

2019 314 citations John K. Erban et al. profile →

Peers

John K. Erban

ONCOL

HEMAT

PRM

M. M. Heiss Germany

Stephen A. Cannistra United States

Evan R. Farmer United States

Jens Atzpodien Germany

G. Bastert Germany

P Selby United Kingdom

Dimitriοs Mavroudis Greece

Martin Gramatzki Germany

Alexander Reinthaller Austria

Jean-Philippe Jaı̈s France

M. M. Heiss Germany

John K. Erban

2.2k ×1.2

ONCOL

745 ×0.7

380 ×0.5

HEMAT

1.2k ×2.1

1.1k ×2.1

PRM

Citations per year, relative to John K. Erban John K. Erban (= 1×) peers M. M. Heiss

Countries citing papers authored by John K. Erban

Since Specialization

Citations

This map shows the geographic impact of John K. Erban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John K. Erban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John K. Erban more than expected).

Fields of papers citing papers by John K. Erban

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John K. Erban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John K. Erban. The network helps show where John K. Erban may publish in the future.

Co-authorship network of co-authors of John K. Erban

This figure shows the co-authorship network connecting the top 25 collaborators of John K. Erban. A scholar is included among the top collaborators of John K. Erban based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John K. Erban. John K. Erban is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chang, Hong, Danai Dima, Joshua Dower, et al.. (2020). Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients. Breast Cancer Research and Treatment. 184(3). 665–674. 13 indexed citations

Dong, Jinghui, Hanyin Wang, Farzad Noubary, et al.. (2019). Timeliness of Treatment Initiation in Newly Diagnosed Patients With Breast Cancer. Clinical Breast Cancer. 20(1). e27–e35. 11 indexed citations

Weisberg, Tracey, et al.. (2019). Development of Phase-Specific Breast Cancer Survivorship Care Plans. Clinical Breast Cancer. 19(6). e723–e730. 4 indexed citations

Zhang, Fang Fang, et al.. (2017). Weight Management: Perception, Interest, and Preferences in Adult Cancer Survivors. Clinical journal of oncology nursing. 21(1). 65–71. 3 indexed citations

Chaulagain, Chakra P., et al.. (2014). Secondary pulmonary alveolar proteinosis in hematologic malignancies. Hematology/Oncology and Stem Cell Therapy. 7(4). 127–135. 32 indexed citations

Swain, Sandra M., Jong‐Hyeon Jeong, Charles E. Geyer, et al.. (2010). Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer. Obstetrical & Gynecological Survey. 65(11). 710–712. 10 indexed citations

Erban, John K., et al.. (2006). Autoimmune Hemolytic Anemia in Patients with Liver Transplants for Primary Biliary Cirrhosis: Three Case Reports and a Review of the Literature. The American Journal of Gastroenterology. 102(1). 197–200. 17 indexed citations

Gradishar, William J., Suparna Wedam, Mohammad Jahanzeb, et al.. (2005). Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Annals of Oncology. 16(8). 1297–1304. 32 indexed citations

Savvides, P., Norma Terrin, John K. Erban, & Harry P. Selker. (2003). Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors. Supportive Care in Cancer. 11(5). 313–320. 16 indexed citations

10.

Eckman, Mark H., et al.. (2002). Testing for Factor V Leiden in Patients with Pulmonary or Venous Thromboembolism: A Cost-Effectiveness Analysis. Medical Decision Making. 22(2). 108–124. 28 indexed citations

11.

Pandya, Kishan J., B.Y. Yeap, Louis M. Weiner, et al.. (2001). Megestrol and Tamoxifen in Patients With Advanced Endometrial Cancer. American Journal of Clinical Oncology. 24(1). 43–46. 44 indexed citations

12.

Wazer, David E., et al.. (1999). The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with ≥ 10 positive axillary nodes. International Journal of Radiation Oncology*Biology*Physics. 44(2). 273–280. 17 indexed citations

13.

Koranda, Pavel, et al.. (1999). Hepatic Perfusion Changes in Patients with Cirrhosis. Clinical Nuclear Medicine. 24(7). 507–510. 13 indexed citations

14.

Valero, Vicente, Stephen E. Jones, Daniel D. Von Hoff, et al.. (1998). A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.. Journal of Clinical Oncology. 16(10). 3362–3368. 188 indexed citations

15.

Wazer, David E., et al.. (1997). The effects of postradiation treatment with tamoxifen on local control and cosmetic outcome in the conservatively treated breast. Cancer. 80(4). 732–740. 38 indexed citations

16.

Comenzo, Raymond L., Marie E. Malachowski, Kenneth B. Miller, et al.. (1995). Large‐volume leukapheresis for collection of mononuclear cells for hematopoietic rescue in Hodgkin's disease. Transfusion. 35(1). 42–45. 28 indexed citations

17.

Schenkein, David P., et al.. (1994). Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.. Journal of Clinical Oncology. 12(11). 2423–2431. 15 indexed citations

18.

Wazer, David E., John K. Erban, Nicholas J. Robert, et al.. (1994). Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection. Cancer. 74(3). 878–883. 75 indexed citations

19.

Miller, K B, David P. Schenkein, Raymond L. Comenzo, et al.. (1994). Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Annals of Hematology. 68(1). 15–20. 25 indexed citations

20.

Larsen, Eric, Alessandro Celi, Gary E. Gilbert, et al.. (1989). PADGEM protein: A receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 59(2). 305–312. 738 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact